Mutant IDH1 Inhibitor Olutasidenib
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Rigel PharmaceuticalsSOUTH SAN FRANCISCO, CA
1 program1
OlutasidenibPhase 1/2Small Molecule1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
2028
2029
Rigel PharmaceuticalsOlutasidenib
Clinical Trials (1)
Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
Start: Aug 2024Est. completion: Jun 2029
Phase 1/2Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials
1 companies competing in this space